Bristol Myers Squibb to Current Information from Revolutionary Cardiovascular Portfolio on the American Coronary heart Affiliation Scientific Classes 2023

Bristol Myers Squibb to Current Information from Revolutionary Cardiovascular Portfolio on the American Coronary heart Affiliation Scientific Classes 2023

[ad_1]

November 6, 2023 —  Bristol Myers Squibb  introduced that analysis throughout the corporate’s cardiovascular franchise shall be introduced on the American Coronary heart Affiliation’s (AHA) annual Scientific Classes, happening November 11-13, 2023 in Philadelphia, Pennsylvania. Scientific trial information to be featured embrace new analyses of the effectiveness of CAMZYOS (mavacamten) in sufferers with and with out gene variants from the Section 3 EXPLORER-HCM research, in addition to new real-world analyses of sufferers with symptomatic New York Coronary heart Affiliation (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) receiving CAMZYOS in scientific follow.

The Bristol Myers Squibb-Pfizer Alliance can even present new information describing disparity in oral anticoagulant utilization patterns amongst commercially insured sufferers with non-valvular atrial fibrillation (NVAF) with excessive stroke threat by geographic area and race within the U.S.

“We’re trying ahead to the chance to showcase new scientific and real-world analyses throughout our cardiovascular franchise, which assist our dedication to develop medicines that tackle the worldwide burden of heart problems,” stated Roland Chen, Senior Vice President, Head of Improvement, Immunology, Cardiovascular & Neurology. “These information on the AHA Scientific Classes proceed to exhibit the profit that therapy with CAMZYOS gives for a broad spectrum of sufferers with symptomatic obstructive hypertrophic cardiomyopathy in scientific research in addition to in scientific follow.”

Key displays embrace:

  • An exploratory subgroup evaluation of the Section 3 EXPLORER-HCM research analyzing therapy effectiveness with CAMZYOS for sufferers with and with out sarcomere gene variants.
  • Findings from an evaluation of an EXPLORER-HCM research assessing the connection between patient-reported KCCQ and physician-assessed NYHA class to reinforce understanding of KCCQ scores and support shared decision-making technique of sufferers and physicians in scientific follow.
  • A retrospective cohort research of claims information from business specialty pharmacies demonstrating excessive real-world adherence to CAMZYOS in >600 sufferers with symptomatic obstructive HCM in the US.
  • An evaluation of Medicare claims information from 2016 to 2020 investigating proof of diagnosis-related disparities in sufferers over 65 with HCM particularly regarding race/ethnicity and county-level disparities.

Abstract of Shows

Choose Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance research at AHA Congress 2023 embrace:

Summary Title Major Writer Sort/# Session Title Time (EST)
Saturday, November 11, 2023
Actual-World Adherence to Mavacamten in Sufferers With Obstructive Hypertrophic Cardiomyopathy in the US Masri, A. Poster – 3002 Medicine, Medicine, and Extra Medicine: New Pharmacologic Insights in Coronary heart Failure Administration 11:30 AM –12:45 PM

Disparities in Pace of Prognosis of Hypertrophic Cardiomyopathy in the US Masri, A. Fast Oral Hearth – 515 Thrilling Developments in Coronary heart Failure Prognosis and Analysis 12:10 PM –12:15 PM

Healthcare Useful resource Utilization and Prices Related With New York Coronary heart Affiliation Purposeful Class in Sufferers With Obstructive Hypertrophic Cardiomyopathy in the US Wang, Y. Poster – 3116 Socioeconomic Disparities and Cardiovascular Well being 3:00 PM –4:15 PM

Biomarker Profile of Sufferers With Atrial Fibrillation and Coronary heart Failure With Preserved Ejection Fraction or Lowered Ejection Fraction: Insights From the ARISTOTLE Trial* Pol, T. Poster – 1059 HFpEF 3:00 PM – 4:15 PM
Sunday, November 12, 2023
Actual-World Sufferers With Obstructive Hypertrophic Cardiomyopathy Handled With Mavacamten: A US Single Heart Expertise Reza, N. Poster – 2160 Hypertrophic, Obstructive, and Takotsubo Cardiomyopathy: From Genetics to Outcomes 11:30 AM –12:45 PM

Monday, November 13, 2023
Relationship Between the Kansas Metropolis Cardiomyopathy Questionnaire Rating and New York Coronary heart Affiliation Class in Sufferers With Hypertrophic Cardiomyopathy: Insights from EXPLORER-HCM Sherrod, C. Poster – 2194 Sport Altering Illness Administration in Hypertrophic, Amyloid, and Cardiomyopathy Care 10:30 AM –11:45 AM

Geographic and Racial Variation in Oral Anticoagulant Remedy Amongst Commercially Insured Sufferers With Non-Valvular Atrial Fibrillation in the US* Atwater, B. E-poster – 2146

Remedy of Arrhythmias: Danger Stratification for Stroke and Stroke Discount Therapies

1:30 PM – 2:45 PM

Response to Mavacamten by Sarcomere Gene Mutation Standing in EXPLORER-HCM Ho, C. Fast hearth oral – 551

The Pharmacologic Administration of Coronary heart Failure: Past Pointers and Paradigms 1:50 PM – 1:55 PM

The Impact of Mavacamten Remedy on Hemolysis Biomarkers in Sufferers With Obstructive Hypertrophic Cardiomyopathy within the EXPLORER-HCM Examine Wang, Z. Fast hearth oral – 553 The Pharmacologic Administration of Coronary heart Failure: Past Pointers and Paradigms 2:10 PM – 2:15 PM

For extra data: https://www.bms.com/

Discover extra AHA23 convention protection right here

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *